Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,212,322 papers from all fields of science
Search
Sign In
Create Free Account
SU 11248
Known as:
SU 011248
, SU011248
, SU11248
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
sunitinib
sunitinib malate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
J. Ebos
,
Christina R. Lee
,
W. Cruz-Muñoz
,
G. Bjarnason
,
J. Christensen
,
R. Kerbel
Cancer Cell
2009
Corpus ID: 10407200
Review
2007
Review
2007
Sunitinib: from rational design to clinical efficacy.
L. Chow
,
S. Eckhardt
Journal of Clinical Oncology
2007
Corpus ID: 20450892
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor…
Expand
Highly Cited
2006
Highly Cited
2006
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
R. Motzer
,
M. Michaelson
,
+12 authors
B. Rini
Journal of Clinical Oncology
2006
Corpus ID: 43889851
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in…
Expand
Highly Cited
2006
Highly Cited
2006
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
S. Faivre
,
C. Delbaldo
,
+10 authors
E. Raymond
Journal of Clinical Oncology
2006
Corpus ID: 8907271
PURPOSE To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase…
Expand
Review
2006
Review
2006
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
J. Desai
,
L. Yassa
,
+8 authors
E. Alexander
Annals of Internal Medicine
2006
Corpus ID: 10409518
Context Sunitinib, a tyrosine kinase inhibitor, has recently been approved for the treatment of gastrointestinal stromal tumors…
Expand
Review
2005
Review
2005
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
A. Arora
,
E. Scholar
Journal of Pharmacology and Experimental…
2005
Corpus ID: 33720
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy…
Expand
Highly Cited
2005
Highly Cited
2005
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
W. Fiedler
,
H. Serve
,
+14 authors
D. Hossfeld
Blood
2005
Corpus ID: 20186455
Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine…
Expand
Highly Cited
2003
Highly Cited
2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic…
D. Mendel
,
A. Laird
,
+20 authors
J. Cherrington
Clinical Cancer Research
2003
Corpus ID: 1801681
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising…
Expand
Highly Cited
2003
Highly Cited
2003
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
A. O'Farrell
,
T. Abrams
,
+12 authors
J. Cherrington
Blood
2003
Corpus ID: 9546814
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In…
Expand
Highly Cited
2003
Highly Cited
2003
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
T. Abrams
,
Leslie B. Lee
,
Lesley J. Murray
,
N. Pryer
,
J. Cherrington
Molecular Cancer Therapeutics
2003
Corpus ID: 28933512
The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE